uniQure N.V.

Status: Publicly traded

Direct answer

uniQure N.V. is publicly traded on NASDAQ under the ticker QURE.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also...

Can you invest in uniQure N.V.?

Yes. uniQure N.V. is publicly traded on NASDAQ under the ticker QURE.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for uniQure N.V.

Detailed equity research is provided by MarketSnap.